FATE THERAPEUTICS INC: 10-Q filed 2026-08-13
What FATE THERAPEUTICS INC reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 35 published measures, 99 facts as tagged in accession 0001193125-26-347988.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-08-13
- Fiscal period
- fiscal Q2 2026
- Accession
- 0001193125-26-347988 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All FATE THERAPEUTICS INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 260,103,000 | USD | |
| At 2025-12-31 | 318,937,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 153,438,000 | USD | |
| At 2026-03-31 | 179,707,000 | USD | |
| At 2025-12-31 | 207,184,000 | USD | |
| At 2025-06-30 | 261,364,000 | USD | |
| At 2025-03-31 | 288,409,000 | USD | |
| At 2024-12-31 | 318,726,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 32,429,000 | USD | |
| At 2025-12-31 | 46,628,000 | USD | |
| At 2025-06-30 | 41,249,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -30,159,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -61,372,000 | USD | 181 |
| 2026-01-01 to 2026-03-31 | -31,213,000 | USD | 90 |
| 2025-04-01 to 2025-06-30 | -34,070,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -71,691,000 | USD | 181 |
| 2025-01-01 to 2025-03-31 | -37,621,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -23,400,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -54,256,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -58,396,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 319,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 2,558,000 | USD | 181 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 2,082,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 3,381,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 1,907,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 3,536,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 1,736,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 1,325,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 38,144,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 62,264,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | -1,595,681,000 | USD | |
| At 2025-12-31 | -1,534,309,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 120,397,390 | shares | 91 |
| 2026-01-01 to 2026-06-30 | 120,215,028 | shares | 181 |
| 2025-04-01 to 2025-06-30 | 118,528,046 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 118,452,214 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 120,397,390 | shares | 91 |
| 2026-01-01 to 2026-06-30 | 120,215,028 | shares | 181 |
| 2025-04-01 to 2025-06-30 | 118,528,046 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 118,452,214 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -0.25 | USD/shares | 91 |
| 2026-01-01 to 2026-06-30 | -0.51 | USD/shares | 181 |
| 2025-04-01 to 2025-06-30 | -0.29 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -0.61 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -0.25 | USD/shares | 91 |
| 2026-01-01 to 2026-06-30 | -0.51 | USD/shares | 181 |
| 2025-04-01 to 2025-06-30 | -0.29 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -0.61 | USD/shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 51,546,000 | USD | |
| At 2025-12-31 | 56,925,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -31,134,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -64,134,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -36,968,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -78,248,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 157,953,000 | USD | |
| At 2025-12-31 | 208,704,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 32,592,000 | USD | |
| At 2025-12-31 | 36,071,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 3,258,000 | USD | |
| At 2025-12-31 | 2,656,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 703,000 | USD | |
| At 2025-12-31 | 916,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 33,216,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 67,515,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 38,875,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 81,784,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 24,387,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 49,090,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 27,430,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 56,566,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 116,694,106 | shares | |
| At 2025-12-31 | 115,359,735 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 1,749,116,000 | USD | |
| At 2025-12-31 | 1,741,259,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | -117,000 | USD | |
| At 2025-12-31 | 116,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 40,554,000 | USD | |
| At 2025-12-31 | 41,609,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 75,675,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 14,904,000 | USD | |
| At 2025-12-31 | 20,024,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 3,480,000 | USD | |
| At 2025-12-31 | 4,131,000 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 0 | USD | |
| At 2025-12-31 | 381,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | -61,372,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -71,691,000 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 8,829,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 18,425,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 11,445,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 25,218,000 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 5,698,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 6,611,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 975,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 2,762,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 2,898,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 6,557,000 | USD | 181 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | -213,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -2,144,000 | USD | 181 |
Inspect the source
- Entity
- FATE THERAPEUTICS INC / CIK 0001434316
- Captured
- 2026-09-20T09:02:50.083Z
- SEC response SHA-256
0d3cfe19fd70310e30c155481681c8ab78f983607cbe93ec4d5e89a1219f24a2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001434316.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))